A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B
- 1 March 2020
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 26 (2) , 278-281
Abstract
Introduction Extended half-life factor IX concentrates (EHL-FIX) can be administered weekly to prevent bleeding for persons with severe haemophilia B. We report the experience of a large UK haemophilia comprehensive care centre using low dose EHL-FIX for persons with severe haemophilia B. Aim The low doses used in real world are approximately half of the doses used in clinical trials. We aim to assess the efficacy and safety of low dose EHL-FIX. Methods Data from a cohort of 13 patients who were switched from standard half-life factor IX (SHL-FIX) to Alprolix(R) (mean dose 31.5 IU/kg) and seven patients who switched from standard half-life factor IX to Idelvion(R) (mean dose 20.2 IU/kg) were included. Results The median annualized bleeding rate was similar for SHL-FIX (median 3, interquartile range [IQR] 1-5) and EHL-FIX (median 3, IQR 1-5.25). Quality of life scores, measured using the European Quality of Life 5 Dimensions assessment were similar for SHL-FIX (median 0.76, IQR: 0.63-0.84) and EHL-FIX (median 0.79, IQR: 0.58-0.88). Conclusion This study shows that EHL-FIX given at low doses can be effective for prevention of bleeding for persons with severe haemophilia B.Keywords
This publication has 12 references indexed in Scilit:
- Real‐life experience in switching to new extended half‐life products at European haemophilia centresHaemophilia, 2019
- The benefits of prophylaxis in patients with hemophilia BExpert Review of Hematology, 2018
- Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentratesThrombosis and Haemostasis, 2017
- Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 studyThe Lancet Haematology, 2017
- Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trialBlood, 2016
- Current management of hemophilia B: recommendations, complications and emerging issuesExpert Review of Hematology, 2014
- Definitions in hemophilia: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2014
- Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia BNew England Journal of Medicine, 2013
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsBlood, 2012
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsBlood, 2012